BridgeBio Pharma BBIO Accrued research and development liabilities
Accrued research and development liabilities at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept bbio:AccruedResearchAndDevelopmentLiabilitiesCurrent.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's accrued research and development liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's accrued research and development liabilities?
- BridgeBio Pharma (BBIO) reported accrued research and development liabilities of $54.43M in Q1 2026.
- How has BridgeBio Pharma's accrued research and development liabilities changed year-over-year?
- BridgeBio Pharma's accrued research and development liabilities increased by 61.8% year-over-year, from $33.63M to $54.43M.
- What is the long-term trend for BridgeBio Pharma's accrued research and development liabilities?
- Over 5 years (2020 to 2025), BridgeBio Pharma's accrued research and development liabilities has grown at a 8.7% compound annual growth rate (CAGR), from $27.29M to $41.44M.
- What does accrued research and development liabilities mean?
- Unpaid costs specifically related to research and development activities performed by third parties.
- How do you interpret accrued research and development liabilities?
- An increase indicates high R&D activity levels, while a decrease may suggest a slowdown in trial enrollment or project completion.
- How does accrued research and development liabilities compare across companies?
- This is a critical metric for biotech companies, with levels directly proportional to the number and phase of active clinical trials.